This study investigated the link between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and eye (ocular) diseases in patients with type 2 diabetes (T2D). The data showed that there was no link between the occurrence of eye diseases and SGLT2is in these patients. Some SGLT2is such as ertugliflozin (Steglatro) and empagliflozin (Jardiance) may protect against eye disease while canagliflozin (Invokana) may promote eye disease. 

This study reported the long-term effectiveness and safety of encorafenib (Braftovi) alone or in combination with binimetinib (Mektovi) or vemurafenib (Zelboraf) alone in patients with BRAF-mutated advanced melanoma. The data showed that the encorafenib plus binimetinib combination lead to long-term effectiveness and no new safety issues in these patients.

This study investigated the effectiveness and safety of zanubrutinib (Brukinsa) versus bendamustine (Treanda) plus rituximab (Rituxan) in untreated patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data showed that zanubrutinib significantly improved the survival without cancer worsening versus bendamustine plus rituximab with manageable side effects in these patients.

This study compared the effectiveness and safety between biodegradable polymer (BP) drug-eluting stents (DES) and durable polymer (DP) DESs in patients with acute coronary syndrome (ACS). The data showed that both stent types demonstrated excellent effectiveness and safety after 1 year. The authors suggested that BP-DES may be more favorable when treating patients with ACS as there was a slight increase in the risks of death or heart attacks in the DP-DES group after 2 years.

The study compared the pregnancy rates for intrauterine insemination (IUI) and in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) in couples with unexplained infertility. The data concluded that IVF/ICSI is a better treatment option than IUI for unexplained infertility.

The study evaluated the effectiveness of intralipid administration to improve in vitro fertilization (IVF) outcomes. The main finding was that injecting intralipid in women during IVF showed promising results in improving pregnancy and live birth rates.

This study compared the effectiveness of TAS-102 (Lonsurf; trifluridine-tipiracil) versus regorafenib (Stivarga) for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that TAS-102 had better oncologic outcomes than regorafenib in these patients.

This study examined the effect of icosapent ethyl (IPE; Vascepa) on major cardiovascular events (MACEs) in statin-treated patients that had previous heart attacks (myocardial infarction; MI). The data showed that patients treated with IPE had large and significant reductions in MACEs.

This study evaluated the effectiveness of combining low-intensity extracorporeal shock wave therapy (Li-ESWT) with a vacuum erectile device (VED) for the treatment of patients with diabetes mellitus (DM) and erectile dysfunction (ED) who were unresponsive to phosphodiesterase-5 (PDE5) inhibitors. The data showed that Li-ESWT combined with VED was more effective than Li-ESWT or VED therapy alone for the treatment of these patients.

This study evaluated the effectiveness and safety of different first-line regimens for the treatment of patients with newly diagnosed multiple myeloma (MM) ineligible for a transplant. The data showed that first-line treatment should be based on daratumumab (Darzalex)-based regimens or the VRd regimen [bortezomib (V; Velcade), lenalidomide (R; Revlimid), and dexamethasone (d; Decadron)] for these patients.